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Previously, we and others have shown that CCAAT displacement protein (CDP) negatively regulates the papillomavirus promoters.
Overexpression of CDP has been shown to inhibit high-risk human papillomavirus virus (HPV) and bovine papillomavirus DNA replication in
vivo presumably through reduction in expression of viral replication proteins, E1 and E2. Sequence analysis of the HPV origin indicates several
potential CDP-binding sites with one site overlapping the E1-binding site. Therefore, CDP could also negatively regulate papillomavirus
replication directly by preventing the loading of the initiation complex. We show here that purified CDP inhibits in vitro HPV DNA replication.
Footprint analysis demonstrated that CDP binds the E1-binding site and the TATA box, and that the binding of purified CDP to the E1-binding site
is decreased by the addition of purified E2 protein. Consistent with this, E2-independent in vitro HPV replication is inhibited by CDP to a greater
extent than E2-dependent replication. These results suggest that binding of E2 at the E2-binding site may play an important role in overcoming the
inhibition of E1 initiation complex formation caused by the binding of negative regulators like CDP to the origin of replication.
© 2006 Elsevier Inc. All rights reserved.Keywords: Human papillomaviruses; Regulation of HPV replication; CCAAT displacement proteinIntroduction
Human papillomaviruses (HPVs) are double-stranded DNA
viruses that infect mucosal or cutaneous epithelia causing
hyperproliferative lesions or warts. HPVs are considered
etiologic agents for the development of cervical cancer (zur
Hausen, 2002). The papillomaviruses are termed ‘high risk’ if
they are associated with development of cancer (e.g., HPV 16,
18, and 31) or ‘low risk’ when seen in warts but not typically
associated with cancer [e.g., HPV 6 and 11 (zur Hausen, 2002)].⁎ Corresponding author. Department of Microbiology and Immunology,
Indiana University School of Medicine, Indianapolis, IN 46202, USA. Fax: +1
317 278 3331.
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doi:10.1016/j.virol.2006.01.047All papillomaviruses have a similar genomic organization
divided into three regions: the long control region (LCR) which
contains the major cis regulatory sequences and the origin of
replication, the early region that encodes six to eight proteins,
and the late region that codes for 2 late structural proteins
(Laimins, 1993; Turek and Smith, 1996). In the case of low-risk
HPV, three promoters have been identified, the E6, E7, and E1
promoters (Karlen et al., 1996; Rapp et al., 1997; Smotkin et al.,
1989). High-risk HPV appears to have only E6 and E1
promoters (Smotkin et al., 1989), although a putative E7
promoter has been recently identified in HPV 16 (Glahder et al.,
2003). All the promoters give rise to polycistronic messages. In
infected epithelia, early genes are expressed in the dividing cells
of the basal cell layer, and as the cells divide, viral DNA is
maintained at approximately 50–100 episomal copies per cell
by limited replication. The productive amplification takes place
as the cells differentiate (Stubenrauch and Laimins, 1999). Very
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this substantial increase in viral replication.
The E1 and E2 proteins and the papillomavirus origin are
essential for viral DNA replication in vivo (Chiang et al.,
1992; Kuo et al., 1994; Remm et al., 1992; Ustav and
Stenlund, 1991; Yang et al., 1991). The remaining machinery
necessary for DNA replication is derived from the host cell.
While both E1 and E2 proteins participate in formation of the
pre-initiation complex, E1 alone is sufficient for initiation and
elongation of viral DNA replication in vitro (Kuo et al., 1994;
Seo et al., 1993; Stenlund, 2003; Yang et al., 1993). The
binding sites for E1 are highly conserved among papilloma-
viruses (Wilson et al., 2002). The E1 DNA-binding site
consists of an A + T-rich palindromic sequence. Using various
techniques, e.g., DNAse I footprinting, mutational analysis of
the binding sites, and sequence analysis, the binding site for
E1 was shown to be an 18 bp imperfect palindrome (Frattini
and Laimins, 1994a, 1994b; Sun et al., 1996; for a review, see
Wilson et al., 2002). The E1-binding site in HPV 11 was
found to be ACTTAATAACAATCTTAG (Sun et al., 1996).
Using the DNA-binding domain of BPV E1, variants of an
AACAAT sequence were identified as the basic E1 DNA
recognition site. There are 6 copies of these sequences
arranged in overlapping arrays in E1-binding sites (Chen and
Stenlund, 2001). E1 proteins expressed and purified from
bacteria or insect cells have been shown to have DNA
binding, ATPase and helicase activities (Bream et al., 1993;
Hughes and Romanos, 1993; White et al., 2001). The
papillomavirus E2 protein has sequence specific DNA-binding
activity. The E2-binding site was mapped to a 12-bp
palindromic sequence ACCN6GGT (Androphy et al., 1987;
Frattini and Laimins, 1994a; Hawley-Nelson et al., 1988;
Hirochika et al., 1988; Li et al., 1989; McBride et al., 1989)
which is present in multiple copies in papillomavirus
genomes. There is a high degree of similarity between various
papillomavirus origins of replication as well as among the
replication proteins. E1 and E2 proteins from HPV11 and
BPV1 can efficiently replicate a plasmid containing the LCR
of HPV 6b and also the origins of many other human and
animal papillomaviruses to various degrees [data not shown
and (Conger et al., 1999; Zou et al., 1998)].
In nearly all systems tested to date, several transcription
factors play important roles in DNA replication. Transcription
factors can activate replication through various mechanisms,
including inducing conformational changes in DNA structure
making it more accessible for binding of initiation proteins, by
remodeling chromatin, and/or by recruiting replication proteins
to initiation complexes (Heintz, 1992 and references therein). In
papillomaviruses, the E2 protein functions as both a replication
and a transcription factor. It binds to and increases the
specificity and affinity of origin binding of papillomavirus E1
protein for the formation of the replication initiation complex
(Chiang et al., 1992; Frattini and Laimins, 1994a; Kuo et al.,
1994; Muller et al., 1994; Sedman and Stenlund, 1995;
Stenlund, 2003; Yang et al., 1991; Zou et al., 1998). Also,
papillomavirus replication is inhibited by transcription factors
such as Yin-yang 1 (YY1), CCAAT displacement protein(CDP), and the TATA-binding protein (TBP). TBP prevents
formation of the HPV 11 E1E2 complex at the origin of
replication in vitro (Hartley and Alexander, 2002), while YY1
has been demonstrated to inhibit replication of high-risk and
low-risk viruses in vivo by sequestering the E2 protein (Lee et
al., 1998). Using transient co-transfection of an HPV 16 origin
containing plasmid and a CDP expression vector into cells
stably expressing E1 and E2 proteins, overexpression of CDP
was shown to repress replication of HPV 16 in vivo (O'Connor
et al., 2000). A similar effect of CDP on the replication of HPV
31 and BPV1 using cell lines containing episomal copies of the
respective viral DNAwas also reported (O'Connor et al., 2000).
The mechanism underlying the repression was not established,
although potential CDP-binding sites were identified by
sequence analysis in the E1 DNA-binding region. CDP and
YY1 both regulate gene expression from the promoters of
papillomaviruses, thereby controlling the amounts of E1 and E2
proteins being expressed. While CDP inhibits transcription
from all promoters of low- and high-risk papillomaviruses (Ai et
al., 1999, 2000; O'Connor et al., 2000), YY1 regulates the E1
promoter of the low-risk papillomavirus (Ai et al., 2000) and the
E6 promoter of the high-risk viruses (Bauknecht et al., 1992;
Kanaya et al., 1997; May et al., 1994). YY1 does not bind the
E1 promoter of high-risk viruses (Ai et al., 2000). Therefore, the
control of replication exerted by CDP and YY1 could be
multifaceted.
CDP is expressed in undifferentiated but not in differen-
tiated cells (Ai et al., 1999; Pattison et al., 1997 and reviewed
in Nepveu, 2001). Full-length CDP has four highly conserved
DNA-binding domains, of which three are Cut repeats (CR1,
CR2, and CR3), and the fourth is a homeodomain (HD)
(Andres et al., 1994; Aufiero et al., 1994; Harada et al., 1995;
Neufeld et al., 1992). CDP binds to a wide range of DNA-
binding sequences with relaxed sequence specificity (Narahari
and Roman, 2002; Nepveu, 2001). The reported sequences
include CCAAT, ATCGAT, TCGATAA, ATCGATTA,
GGGGCGGTTGTATATCAGGGCC, Sp1 sites, and AT-rich
matrix attachment regions (Chattopadhyay et al., 1998;
Coqueret et al., 1998; Liu et al., 1997; Luo and Skalnik,
1996; Wang et al., 1999).
This report shows that CDP specifically inhibits in vitro
replication of a plasmid containing the HPV 11 origin of
replication. The DNA-binding sites for CDP on the HPV 6 and
11 origin of replication were mapped to three sites using the
nuclease protection assay. CDP inhibits E2-independent in vitro
replication of HPV 11 to a greater extent than E2-dependent
replication. Data are also presented to show that E2 decreases
the binding of CDP at the E1-binding site. Based on our present
and previous results, we conclude that CDP inhibits papillo-
mavirus replication during the initial infection by (1) binding
the HPV promoters and inhibiting transcription of the
replication proteins in undifferentiated cells and (2) competing
with the replication proteins for DNA binding. We therefore
propose that E2, in addition to enhancing the binding of E1,
plays an important role in replication initiation by outcompeting
host cell negative regulators, such as CDP, for the viral origin of
replication.
Fig. 1. (A) Sequence homology between the origin of replication of HPV 11 and
6. The differences between the two sequences are marked by asterisk (*). The
locations of the E1- and E2-binding sites are shown. (B) CDP inhibits low-risk
papillomavirus DNA replication in vitro. In vitro replication assays were carried
out as described in Materials and methods. Lane 1 shows replication of the HPV
11 origin containing plasmid in the presence of the elution buffer used in CDP
purification. Lanes 2, 4, 6, and 8 show increasing inhibition of replication in the
presence of increasing concentrations of purified truncated CDP, His-
CR2CR3HD. Lanes 3, 5, 7, and 9 represent replication reactions with
corresponding amounts of CDP as in lanes 2, 4, 6, and 8 that were first
inactivated by heating at 95 °C for 10 min (indicated by ΔCDP in the figure).
Lane 10 is a control showing no replication in the absence of added
papillomavirus replication proteins E1 and E2. Lane 11 represents replication
in the absence of added E2. (C) CDP inhibits low-risk papillomavirus replication
but not SV40 replication in vitro. In vitro replication assays were carried out and
the replication intermediates quantitated as described in Materials and methods.
The replication seen in the absence of CDP was set at 100 (control), and the
replication observed in the presence of CDP was calculated as percent of control,
and the values were plotted as a graph. The filled circles and the filled triangles
represent replication of papillomavirus and SV40, respectively, in the presence
of increasing amounts of CDP. The results shown are a representative result from
three independent HPV ori experiments and two SV40 ori experiments.
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Overexpression of CDP inhibits replication of high-risk HPV
and bovine papillomavirus in vivo (O'Connor et al., 2000) and
leads to inhibition of low-risk HPV 6 replication in vivo (data
not shown). CDP binds to and represses expression from the E6
and E1 promoters of both low-risk and high-risk HPV, thereby
regulating the expression of E1 and E2 genes (Ai et al., 1999;
O'Connor et al., 2000). The origin of replication in papilloma-
viruses overlaps the E6 promoter region (Chiang et al., 1992;
Frattini and Laimins, 1994b; Ustav and Stenlund, 1991; Yang et
al., 1991). It is, therefore, not clear whether this inhibition of
replication is due to decreased transcription of replication
proteins and/or competition for DNA binding with the viral
replication proteins at the origin (O'Connor et al., 2000).
Experiments were conducted to determine whether CDP could
affect cell-free replication assays using a plasmid containing the
HPV origin of replication and purified E1 and E2 proteins,
thereby bypassing any role for transcription control.
Purified CDP inhibits replication of low-risk papillomavirus
in vitro
We used a highly purified truncated form of CDP, containing
the Cut repeats 2, 3, and the HD (CR2CR3HD). This truncated
protein recognizes the consensus DNA-binding sequence for
CDP [ATNNAT (Moon et al., 2001)] and is amenable to over
production and purification (Goulet et al., 2002). An efficient in
vitro system using purified HPV 11 E1 and E2 proteins capable
of replication of either an HPV 6 or HPV 11 origin containing
plasmid was utilized. The replication origins of HPV 6 and 11
have a 95% sequence homology with two missing nucleotides
in HPV 6 and a difference in 7 nucleotides between the two
(Fig. 1A). In the absence of E1 and E2 proteins no replication is
seen, while a very small amount of form I DNA repair is
observed (Fig. 1B, lane 10). Efficient replication of the origin
containing plasmid is seen when both E1 and E2 proteins are
added to the reaction, even in the presence of the elution buffer
used in CDP purification [buffer control (lane 1)]. Omission of
E2 from the reaction greatly reduces replication demonstrating
that the replication is E2-dependent under these conditions (lane
11). Addition of increasing amounts of purified CDP results in
dose-dependent inhibition of replication (lanes 2, 4, 6, 8). No
inhibition is seen when the protein fraction was heat inactivated
at 95 °C for 10 min (lane 3, 5, 7, 9).
The fairly high level of CDP required for inhibition of HPV
DNA replication led us to question whether this was a specific
effect. We noted that the CDP-binding site is relatively
nonspecific [ATNNAT (Moon et al., 2000); CCAAT (Andres
et al., 1994)], and a quick manual search revealed at least 18
potential CDP-binding sites in the plasmid backbone, pUC19.
Further, we have previously shown that the pUC19 plasmid can
compete with papillomavirus DNA sequences for CDP binding
(Narahari and Roman, 2002; Pattison et al., 1997). Hence, it is
likely that the high amounts of CDP required to inhibit
replication (Fig. 1B) are due to CDP binding at multiple sites in
the pUC19 backbone. To rule out nonspecific inhibition of
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the purified CDP fraction, the effect of CDP was compared in
papillomavirus and SV40 replication reactions (Fig. 1C). The
backbone of the SV40 origin containing plasmid is also pUC19.
In each case, the replication intermediates were quantitated and
a graph plotted as percent replication of control (with no CDP
added). A dose-dependent inhibition of papillomavirus replica-
tion with the addition of increasing amounts of CDP was
observed as above (Figs. 1B, C, filled circles), but no inhibition
of SV40 replication was seen, even at the higher amounts of
CDP used (Fig. 1C, filled triangles). This result indicates that
the CDP inhibition of papillomavirus replication is specific.
Two mechanisms of inhibition that are not mutually exclusive
could explain this result. First, if CDP binds E1 and/or E2 the
viral proteins could be sequestered, rendering E1 and/or E2
unavailable for replication, as is seen with YY1 (Lee et al.,
1998). Second, CDP could bind DNA and prevent the formation
of a replication initiation complex at the origin.
E2 and CDP do not show appreciable interaction
To test for the presence of any physical interaction between
E2 and CDP, GST-pull down experiments were performed using
purified GST-E2 and cytoplasmic extract made from Sf-9 cells
overexpressing His-tagged CDP (Sf-9/CDP). CDP was detect-
able when high amounts of purified GST-E2 (50 μg) were used
in the pull down experiments (Fig. 2, lane 4). No CDP was
pulled down when mixed with similar amounts of GST alone
(Fig. 2, lane 3). Lanes 1 and 2 show 5% of the input reactions
containing either GST and Sf-9/CDP extract or GST-E2 and Sf-
9/CDP, respectively, to validate comparable protein amounts
used for the pull down. These results demonstrate that less than
1% of the CDP present in the extracts could be co-precipitated
even with a vast excess of GST-E2. No detectable CDP was
pulled down with either 10 or 20 μg GST-E2 in the pull down
assay (data not shown), suggesting again that no significant
interaction exists between CDP and E2. Interactions between
CDP and E1 or E2 were also tested using in vitro translated
35[S] methionine-labeled His-E1, His-E2, and CDP. The His-
tagged proteins were bound to Ni-NTA beads and extensively
washed and then incubated with in vitro translated, labeled
CDP. Protein complexes bound to the beads were sedimented,
washed, and separated on SDS-PAGE. No detectable CDP wasFig. 2. E2 and CDP exhibit negligible protein–protein interaction. GST-pull
down experiments were carried out as described in Materials and methods. The
Western blot was probed with anti His-antibodies for the presence of His-tagged
CDP. Lanes 1 and 2 represent 5% of the starting reaction with Sf-9/CDP extract
and either GST or GST-E2, respectively. Lanes 3 and 4 represent His-tagged
proteins pulled down with GST or GST-E2, respectively.observed, despite long exposures, in either E1 or E2 pull down
lanes (data not shown). The above results suggest that there is
no significant interaction between CDP and the papillomavirus
replication proteins E1or E2.
CDP binds the HPV origin at three places
The lack of physical interaction between CDP and
papillomavirus replication proteins suggests that the inhibition
of HPV replication observed in the presence of CDP (Fig. 1B) is
probably due to competition for DNA binding. The binding
sites for CDP in the low-risk HPV origin have not been
previously identified. CDP binds A − T-rich DNAwith relaxed
sequence specificity. Five A − T-rich regions in the HPV 6
origin that could be potential CDP-binding sites were identified
based on their similarity with the consensus binding site
[ATNNAT (Moon et al., 2000)] and published reports (Fig. 3A).
Among the putative sites identified, one site overlaps the E1-
binding site (E1BS), and the other overlaps the TATA box that is
directly adjacent to the downstream E2-binding site (E2BS)
(Fig. 3A).
To identify the CDP-binding sites, footprint analysis was
performed using His-CR2CR3HD. DNase I footprint analysis
on the HPV 6 origin gave three A − T-rich footprints (Fig. 3B).
A strong footprint by CDP was seen in the E1 DNA-binding
region (identified based on published reports, see Introduction)
spanning the entire E1BS and the A6 tract (Fig. 3B, lane 2 vs.
lane 4). The footprint overlapping the E1 DNA-binding region
implies that CDP could compete with E1 protein to bind the
origin and inhibit papillomavirus replication. Two other short
footprints were also clearly visible downstream of the E1BS.
One footprint spanned approximately 10 nucleotides, over-
lapped the last few bases of the E2 footprint (see below) and
completely covered the TATA box present 3′ to the E2-binding
sites. The other footprint covered 10 nucleotides and was
present downstream of the TATA box. Two footprints of CDP at
the E1BS and TATA box were also obtained when the HPV 11
origin was used as probe (Fig. 3C, lane 1 vs. lane 3), similar to
that seen with the HPV 6 origin. Footprints at similar sites were
obtained whether the top strand or the bottom strand of the HPV
origin was used as the probe (data not shown).
Footprint analysis was also performed using the HPV 6 E2
protein expressed and purified as a GST fusion protein from
bacteria. As expected, the GST-E2 protein gave footprints over
the E2-binding sites present in the origin (Figs. 3B and C, lane 3
and 2, respectively). The footprints extended a few base pairs
beyond the consensus E2-binding sites. As noted above, the E2
footprint overlapped the CR2CR3HD footprint at the TATA box
by a few base pairs (Figs. 3B and C, compare lane 2 vs. lane 3,
and lane 1 vs. 2, respectively).
Decreased CDP binding at the origin is observed in the
presence of E2
As pointed out above, footprint analysis suggests that CDP
and E1 can compete for DNA-binding at the E1-binding site.
CDP also binds at the TATA box that is present immediately
Fig. 4. E2 alters CDP binding at the origin of replication. The reverse strand of
the HPV 6 origin was labeled and used for DNase I footprinting as described in
the Materials and methods. Lane 1 represents the DNase I digestion pattern in
the absence of any added proteins. Lanes 2 and 3 represent the footprints
obtained with the purified His-CR2CR3HD CDP truncation or GST-E2,
respectively. Lane 4 shows the decrease in CDP binding at the E1 site in the
presence of GST-E2. The footprints for CDP and E2 are indicated by two-
headed arrows in lanes 2 and 3, respectively. Also shown is a schematic
representation of the HPV 6/11 origin, with the E1- and E2-binding sites, and the
TATA box region, identified based on previously published sequences (see
Introduction).
Fig. 3. (A) Potential CDP-binding sites on the HPV 6 origin. The sequence of
the HPV 6 origin used in the footprint analysis is shown. The E1-binding site,
identified based on the other published E1-binding site sequences, is indicated
with borders on all the sides. The consensus E2-binding sites are underlined.
Potential CDP-binding sites are shown in lower case letters. Some of the
published CDP-binding sites are also shown in the figure. (B) CDP and E2
footprints on the HPV 6 origin. Reverse strand of the HPV origin was labeled
and used for DNase I footprinting as described in Materials and methods. Lane 1
represents the ‘G’ ladder. Lanes 2 and 3 represent the footprints obtained with
purified truncated CDP (His-CR2CR3HD) or GST-E2, respectively, on the HPV
6 origin. Lane 4 represents the DNase I digestion pattern in the absence of any
added proteins. (C) CDP and E2 footprints on the HPV 11 origin. Lanes 1 and 2
represent the footprints obtained with purified truncated CDP (His-
CR2CR3HD) or GST-E2, respectively, on the HPV 11 origin. Lane 3 represents
the DNase I digestion pattern in the absence of any added proteins. The
footprints for CDP and E2 are indicated by two-headed arrows in lanes 2 and 3,
respectively. Also shown is a schematic representation of the HPV 6/11 origin,
with the E1- and E2-binding sites, and the TATA box region, identified based on
previously published sequences (see Introduction).
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GST-E2 and His-CR2CR3HD showed some degree of overlap,
raising the possibility that a competition for DNA-binding could
exist between CDP and E2. Also, binding of the C-terminal
domain of TBP at the TATA-binding site prevents E2 from
binding DNA at the E2BS, both in the presence and absence of
E1 (Hartley and Alexander, 2002). Therefore, footprint analysis
was performed to establish the effect of E2 on the binding of
CDP to the HPV origin (Fig. 4). Lanes 2 and 3 represent the
footprints seen with CDP or GST-E2 alone, respectively. Wehave consistently observed that, in the presence of GST-E2,
there was a decrease in the binding of CDP at the E1-binding
site (Fig. 4A, lane 4 compared to lane 2). This suggests that
binding of GST-E2 at the E2BS decreases binding of CDP at the
E1-binding site, thereby providing increased opportunity for E1
to bind to the origin and initiate HPV DNA replication.
However, there was an increase in the CDP binding, both at and
downstream of the TATA box in the presence of E2. The above
results suggest that (a) both CDP and E2 can simultaneously
bind the origin and (b) in the presence of E2, there is a shift in
CDP binding from the E1BS to the TATA box site downstream
of the E2BS.
CDP inhibits E2-independent replication to a greater extent
than E2-dependent replication
Given that E2 can decrease CDP binding at the E1BS (Fig.
4A, lane 4 compared to lane 2), CDP should inhibit in vitro
papillomavirus DNA replication to a greater extent in the
absence of E2. To test this hypothesis, E2-independent in vitro
HPV 11 DNA replication was evaluated for the effect of CDP
(Fig. 5B, lane 2). The level of CDP-mediated inhibition was
compared for replication reactions in the presence and absence
of E2 (compare Figs. 5A and B). Only 45% of E2-dependent
replication was inhibited by 16 μg of CDP (Fig. 5A, lane 2),
whereas the same amount of CDP inhibited the E2-independent
replication by greater than 80% (Fig. 5B, Lane 3). This suggests
that E2, which binds to the origin with higher affinity than E1
Fig. 5. E2-independent HPV replication shows greater sensitivity to CDP
inhibition. (A) Effect of CDP on E2-dependent HPV replication. In vitro
replication assays were carried out as described in Materials and methods. Lane
1 shows replication of the HPV 11 origin containing plasmid. Lane 2 shows
reduced replication in the presence of 16 μg of purified truncated CDP, His-
CR2CR3HD. Lane 3 represents replication in the presence of 16 μg of purified
His-CR2CR3HD that was first inactivated by heating at 95 °C for 10 min
(indicated by Δ in the figure). Lane 4 is a control showing no replication in the
absence of added papillomavirus replication proteins E1 and E2. (B) Effect of
CDP on E2 independent HPV replication. Lane 1 represents a replication
reaction in the absence of HPV 11 E1 protein. Lane 2 represents E2-independent
replication of an HPV 11 origin-containing plasmid in the presence of E1
protein. Lane 3 shows inhibition of replication by 16 μg of the truncated CDP
(His-CR2CR3HD). Lane 4 represents a replication reaction in the presence of
16 μg of His-CR2CR3HD that was first inactivated by heating at 95 °C for
10 min (indicated by Δ in the figure).
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thereby allowing for more efficient viral DNA replication in the
presence of the negative regulator CDP.
Discussion
In papillomaviruses, DNA replication is dependent upon
expression and efficient interaction between the viral replication
initiator proteins E1 and E2 and the papillomavirus origin of
replication. Interaction between E1 and E2 proteins leads to the
formation of an (E1)2 (E2)2 complex that binds with high
affinity to the E2-binding sites. The importance of the E2
protein in papillomavirus replication is demonstrated by an
absolute requirement for an E2BS and the E2 protein for
efficient replication in vivo, even in the absence of the E1-
binding site (Chiang et al., 1992; Remm et al., 1992; Sverdrup
and Khan, 1995; Ustav et al., 1993). Therefore, factors that
control the expression of E1 and E2 protein, influence the
interaction between E1 and E2, or modify the activity of these
proteins could control virus replication.
CDP represses transcription from all the papillomavirus
promoters (Ai et al., 1999; O'Connor et al., 2000), making it a
model candidate for a general controller of viral gene
expression. In addition to exerting inhibitory effects through
decreasing gene expression, CDP could compete with E1 for
DNA-binding at the origin, thereby preventing formation of the
replication initiation complex. Footprint analysis with CDP
identified a CDP-binding site overlapping the E1BS. We have
investigated the effect of CDP on the DNA-binding activity of
papillomavirus E1 protein and found that E1 alone does notefficiently compete with CDP for DNA-binding in vitro (data
not shown). On the other hand E2 alone can alter the binding of
CDP to DNA in a purified system (Fig. 4, lane 2 vs. lane 4). This
competition occurs even in the absence of extensive overlap in
the E2 and CDP-binding sites. We also observed that the
binding of E2 to origin DNAwas either enhanced or stabilized
in the presence of a nuclear extract made from human cells (data
not shown). Previously, poly (ADP-ribose) polymerase 1
(PARP-1) was shown to enhance DNA binding of HPV 18 E2
to the E6 promoter (Lee et al., 2002). PARP-1 complexes with
E2 and activates transcription of E2-dependent genes (Lee et al.,
2002). It is possible that complexes formed between E2 and
nuclear protein(s) such as PARP-1 may help direct the outcome
of the competition between CDP and E2. This would be
particularly relevant during the initial stages of viral infection in
the epithelial basal cells where the levels of CDP would be
higher than the E2 levels. Also, identification of the nuclear
protein(s) bound to E2 may shed yet more light on the factors
involved in regulating papillomavirus DNA replication.
Our results add a new aspect to the importance of E2BS and
the E2 protein in papillomavirus replication. Recruitment of E1
to the origin is essential for the formation of the replication
initiation complex. Our results suggest that one of the functions
of E2 protein in papillomavirus DNA replication appears to be
to help recruit E1 to the origin by overcoming the repression of
E1 DNA binding due to the presence of cellular DNA-binding
proteins. Since there are three E2BS in the origin of replication
of HPV 6 and 11 surrounding the E1BS, it is possible that
occupation of one or more of the sites by either E2 or an E2:
protein complex either prevents or displaces CDP bound at the
E1BS, thereby allowing the site to be bound by E1.
The CDP footprint over the TATA box of the E6 promoter
also suggests that competition with TBP for DNA binding could
be one of the modes of transcription inhibition by CDP. HPV E2
has been reported to bind TBP (Enzenauer et al., 1998; Hartley
and Alexander, 2002). Competition for DNA binding between
TBP and E2 has also been demonstrated, providing a possible
mechanism for inhibition of papillomavirus replication by TBP
(Hartley and Alexander, 2002). Our data suggest that the
competition could be between more than two proteins with CDP
competing for DNA binding at the same region. Binding of
CDP at this site would inhibit transcription from the E6
promoter, thereby decreasing the amount of replication proteins
made in the basal cells. Binding of E2 would allow replication
to proceed, while binding of TBP to the E6 promoter would lead
to transcription.
Both the E6 and E7 proteins of the high-risk HPV 31 are
required for the episomal maintenance of the HPV genome
(Thomas et al., 1999). HPV E7 has been shown to bind TBP
(Enzenauer et al., 1998; Maldonado et al., 2002; Massimi et al.,
1996). The interaction between E7 and TBP inhibits the DNA-
binding activity of TBP (Maldonado et al., 2002). Therefore, it
is possible that one of the functions of E7 is to sequester TBP,
thus removing it from the replication site. Using GST-pull down
assays, we found that HPV 16 E7 specifically binds to two other
inhibitors of HPV replication namely CDP and YY1 (data not
shown). Thus, taking our data and the data of others together,
308 J. Narahari et al. / Virology 350 (2006) 302–311the E7 protein may act as a sink to remove inhibitors of HPV
replication.
Based on our results we propose that the outcome of the
replication cycle of papillomavirus in vivo would be based on
the amount of the E1 and E2 proteins expressed, competition
between E1 and E2 and cellular DNA-binding proteins, the
interaction between nuclear proteins and E2, and protein–
protein interactions between E7 and the cellular proteins.
Materials and methods
Plasmids
For the expression of full-length HPV 6 E2 protein as a GST
fusion in bacteria, nucleotides 2723–3900 of the HPV6 W50
(Farr et al., 1991) genome were amplified using the primers
containing BamH1 and EcoR1 restriction sites (in the forward
and reverse primers, respectively). The PCR product was
digested with BamH1 and EcoR1 and cloned into the
corresponding restriction sites in pGEX-3X (Amersham-
Pharmacia Biotech) to generate pGST-E2. To generate the
plasmid pHPV6ori, nucleotides 7968-96 were amplified from
the HPV6 W50 (Farr et al., 1991) genome and cloned into
pUC19 at the Sma I site. The baculovirus expressing full-length
CDP and the His-tagged CR2CR3HD expressing plasmid were
obtained from Dr. Alan Nepvue, Canada. The HPV 11 ori-
containing plasmid p7874-99, containing one E1BS and three
E2BS, has been previously described (Chiang et al., 1992; Kuo
et al., 1994). The SV40 replication plasmid pSV011 has been
previously described (Prelich and Stillman, 1988; Stillman
et al., 1985).
Preparation of extracts and purification of proteins
Sf-9 cells were infected with the baculovirus expressing His-
tagged full-length CDP. 72 h post-infection, the Sf-9 cells were
spun down, washed twice with PBS, resuspended in hypotonic
buffer [20 mM Tris–HCl, pH 7.9, 10 mM KCl; 1.5 mMMgCl2;
0.5 mM DTT and complete protease inhibitor cocktail (Roche
Biochemicals, IN, USA)] and incubated on ice for 15 min. The
cells were disrupted using the tight pestle of the dounce
homogenizer (25 strokes) and centrifuged at 30,000×g for
30 min, and the supernatant (cytoplasmic extract) was stored as
aliquots.
GST-E2 was expressed and purified from E. coli strain BL21
(Stratagene). Briefly, BL21 transformed with pGST-E2 was
grown in LB media at 37 °C and at an OD of 0.6 was induced
with 1 mM IPTG for 3 h. The culture was centrifuged at
6000 rpm for 10 min, bacterial pellet washed once with lysis
buffer [PBS containing 1 mM DTT and complete protease
inhibitor cocktail (Roche Biochemicals)], the bacteria resus-
pended in lysis buffer and disrupted by sonication. The lysate
was spun at 30,000×g for 30 min at 4 °C and GST-E2 purified
from the supernatant using glutathione Sepharose according to
the manufacturer's protocol (Pharmacia-Amersham). HPV 11
EE-E1 was purified from baculovirus-infected Sf-9 cells as
previously described (Chiang et al., 1992; Conger et al., 1999;Kuo et al., 1994). HPV 11 BB-E2 (Conger et al., 1999) was
purified from E. coli strain BL21(DE3)pLysS (Stratagene) as
detailed previously (Lin et al., 2002). His-tagged CR2CR3HD
was expressed and purified from E. coli strain BL21(DE3)
pLysS (Stratagene) according to the published protocol (Goulet
et al., 2002).
Cell free HPV 11 replication assay
The HPV 11 ori-containing plasmid p7874-99 (Chiang et al.,
1992; Kuo et al., 1994) was purified using a commercial
plasmid maxiprep kit (Qiagen) followed by separation on a 5–
20% sucrose gradient. 293 extract was prepared by hypotonic
dounce and clarified by centrifugation at 100,000×g as
previously described (Stillman and Gluzman, 1985). Replica-
tion assays were performed as described (Kuo et al., 1994; Liu
et al., 1995), with some modifications. Replication reactions
were carried out in the presence or absence of BB-E2. E2-
dependent reactions were performed with 40 ng EE-E1 and
20 ng BB-E2, while E2-independent reactions contained 50 ng
of EE-E1. Twenty-microliter replication reactions containing
30 ng of p7874-99 were incubated for 1 h at 37 °C in the
presence or absence of purified truncated CDP, His-
CR2CR3HD. Two μCi of α[32P] dATP was then added, and
the reaction was incubated at 37 °C for an additional hour. The
reaction was terminated upon addition of stop buffer (20 mM
Tris (pH 7.5), 10 mM EDTA, 0.1% SDS, 2 μg proteinase K) and
incubated at 37 °C for 30 min. Following phenol/chloroform
extraction and ethanol precipitation, the replication products
were resolved on a 0.8% agarose gel, dried and analyzed using a
Phosphorimager (Bio-Rad). To minimize incorporation due to
repair products in the analyses, replication products were
quantitated by densitometry of replication intermediates (R.I.).
SV40 in vitro replication assays were performed as previously
detailed (Han et al., 1999), with the following modifications.
Either purified CDP or heat inactivated CDP was added to in
vitro replication reactions, followed by incubation for 90 min at
37 °C. Reactions were analyzed as described above for HPV
replication reactions.
DNase I footprinting
The labeled HPV6 origin was generated by PCR using 5′
CCACACCCTACATAT 3′ and 5′GCCTCGTTTGCTAAA 3′as
primers. The reverse primer was end labeled using [32P]γ-ATP
and T4 polynucleotide kinase and used in PCR along with
unlabeled forward primer. The PCR product was purified
following native PAGE by soak elution. DNase I footprinting
was carried out as previously described (Harada et al., 1995).
Briefly, 50,000 cpm of the probe was incubated on ice with
either 1.25 μg of purified His-CR2CR3HD or 1.25 μg of
purified GST-E2 protein in 25 μl reaction containing 25 mM
Tris–HCl, pH 7.5; 25 mM NaCl; 4% polyvinyl alcohol and
20 ng of poly (dI–dC) for 15 min on ice. 75 μl of Ca2+/Mg2+
buffer was added to each reaction and incubated for 90 s at room
temperature. 0.046U of DNase I was then added, and incubation
continued for additional 90 s. DNase I was arrested using 100 μl
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and vortexed. The DNA was extracted by phenol:chloroform:
isoamyl alcohol and precipitated by ethanol. The samples were
electrophoresed through a 6% denaturing polyacrylamide
sequencing gel in 1× Tris–borate–EDTA buffer. The gels
were dried, and the bands were visualized by autoradiography.
Protein–protein interactions
50 μg of purified GST-E2 or GST alone was mixed with
500 μg of Sf-9/CDP extracts in 500 μl of binding buffer (50 mM
Tris–HCl; 200 mM NaCl; 5 mM β-mercaptoethanol and 1 mM
PMSF) with rocking at 4 °C for 1 h. The samples were then
clarified at 16,000×g for 1 min to remove insoluble matter. 85%
of the sample was transferred into a new tube containing 25 μl
of pre-equilibrated glutathione-Sepharose beads and rocking
continued for 1 h. The tubes were centrifuged at 325×g for
2 min, and the supernatant was discarded. The beads were
washed three times with 1.0 ml of wash buffer (Binding buffer
with 0.1% NP-40). Finally, the beads were resuspended in 30 μl
of 1× SDS-PAGE buffer, boiled, and separated on a 10% SDS-
PAGE gel. The proteins were analyzed by Western blot using
anti-His antibodies (Pierce Biotechnology, IL) to probe for the
presence of His-tagged CDP.
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